Djahna Thomas, MD
Allergy & Immunology · Silver Spring, MDNPI 1629238555
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (59.7%), food and beverage and education — rather than concentrated in one kind of arrangement. Genentech USA, Inc. accounts for 61.0% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2020 at $1,551 and has fallen 98.6% since, to $22 in 2024.
Across 54 payments — averaging $41.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$1K
- AstraZeneca$244
- Regeneron Healthcare Solutions, Inc.$180
- GSK$134
- Alk-abello, Inc$55
- Kaleo, Inc.$53
- plus $215 from 8 others
What the payments were for
- Consulting fees$1,35060%
- Food & beverage$88839%
- Education$221%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 4 | $1,379 |
| AstraZeneca | 13 | $244 |
| Regeneron Healthcare Solutions, Inc. | 9 | $180 |
| GSK | 7 | $134 |
| Alk-abello, Inc | 3 | $55 |
| Kaleo, Inc. | 4 | $53 |
| Optinose US, Inc. | 3 | $46 |
| Pfizer | 3 | $45 |
| Sanofi | 2 | $37 |
| Biocryst US Sales Co., LLC | 2 | $35 |
| Mylan Pharmaceuticals Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Novartis | 1 | $11 |
| Phadia US Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XOLAIR$1,350
How this compares
$2,260 in reported general payments places this provider in the 55th percentile of 105 allergy & immunology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $10,924 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 21 | $780 |
| Montelukast Sodium | 27 | $293 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $134 | $10,92411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 105 allergy & immunology providers in Maryland.
Other allergy & immunology in Silver Spring
- Angela CanadySilver Spring$15K
- Martin CorreaSilver Spring$8K
- Jenni YoonSilver Spring$3K
- Vasif KalfaSilver Spring$3K
- Nkiruka ErekosimaSilver Spring$3K
- Antoine AzarBaltimore$612K
- Mark ScarupaWheaton$508K
- Sally BaileyBaltimore$344K
- Manav SinglaWhite Marsh$168K
- Sudhir SekhsariaRockville$87K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.